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Abstract
Background
Granulocyte-colony stimulating factor (G-CSF) mobilises endogenous haematopoietic stem
cells and enhances recovery in experimental stroke. Recovery may also be dependent on
an enriched environment and physical activity. G-CSF may have the potential to enhance
recovery when used in combination with physiotherapy, in patients with disability late after
stroke.
Methods
A pilot 2 x 2 factorial randomised (1:1) placebo-controlled trial of G-CSF (double-blind), and/
or a 6 week course of physiotherapy, in 60 participants with disability (mRS >1), at least 3
months after stroke. Primary outcome was feasibility, acceptability and tolerability. Second-
ary outcomes included death, dependency, motor function and quality of life measured 90
and 365 days after enrolment.
Results
Recruitment to the trial was feasible and acceptable; of 118 screened patients, 92 were eli-
gible and 32 declined to participate. 60 patients were recruited between November 2011
and July 2013. All participants received some allocated treatment. Although 29 out of 30
participants received all 5 G-CSF/placebo injections, only 7 of 30 participants received all
18 therapy sessions. G-CSF was well tolerated but associated with a tendency to more
adverse events than placebo (16 vs 10 patients, p = 0.12) and serious adverse events
(SAE) (9 vs 3, p = 0.10). On average, patients received 14 (out of 18 planned) therapy
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sessions, interquartile range [12, 17]. Only a minority (23%) of participants completed all
physiotherapy sessions, a large proportion of sessions (114 of 540, 21%) were cancelled
due to patient (94, 17%) and therapist factors (20, 4%). No significant differences in func-
tional outcomes were detected in either the G-CSF or physiotherapy group at day 90 or
365.
Conclusions
Delivery of G-CSF is feasible in chronic stroke. However, the study failed to demonstrate
feasibility for delivering additional physiotherapy sessions late after stroke therefore a defini-
tive study using this trial design is not supported. Future work should occur earlier after
stroke, alongside on-going clinical rehabilitation.
Trial Registration
ISRCTN.com ISRCTN16714730
Introduction
Stroke is the second leading cause of disability worldwide, with half of survivors being depen-
dent on other people six months later[1]. The incidence of stroke increases almost exponen-
tially with age and, in combination with an aging population, the burden of stroke to survivors,
their families and society is increasing.
Rehabilitation is thought to promote functional recovery through neuroplastic changes and
evidence suggests plasticity extends beyond the sub-acute stage.[2] Despite this, the majority of
patients do not receive rehabilitation therapy beyond three months, although some receive
community input for up to six months post stroke. The dose, method and intensity of therapy
appear to be important and most effective when delivered as high intensity task specific prac-
tice.[3] Therapy at home may be beneficial,[4] but the long term benefit of therapy in chronic
stroke is not known.[5] In experimental stroke, ‘top-up’ bursts of therapy improve functional
outcome[6] but this has not been demonstrated in clinical studies.
Pharmacological agents may increase the benefit of intensive therapy.[7] Potential thera-
peutic options for pharmacological enhancement of recovery include neurochemical
approaches, using agents such as amphetamines,[8] or SSRI’s.[9] Another approach is a neu-
roreparative paradigm, using agents such as stem cells, or agents that release endogenous stem
cells.
Granulocyte Colony Stimulating Factor (G-CSF) mobilises endogenous haematopoietic
(CD34+) bone marrow stem cells into the circulation and is routinely used in stem cell trans-
plantation in haematological malignancy.[10] G-CSF has a multi-modal action that has the
potential to be both neuroprotective (anti-apoptotic) and neuroreparative, the latter through
mechanisms that include stem cell mobilisation, neurogenesis and angiogenesis. In experimen-
tal models of stroke, when given soon after infarct, G-CSF improves recovery.[11, 12] In clini-
cal stroke, G-CSF when given in similar doses as used in haematology, was effective at
mobilising CD34+ stem cells[13] and a number of trials have since been completed in acute
[14, 15] and sub acute stroke.[16] In the largest study,[15] G-CSF showed no evidence of effi-
cacy in 328 patients with hyperacute stroke. However, G-CSF was given intravenously and
unexpected haemodynamic effects were reported potentially counteracting any potential
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beneficial effects of G-CSF. Meta-analysis of all studies to date showed a non-significant reduc-
tion in early impairment but no effect on functional outcome.[17]
In an experimental model of later administration, G-CSF when given with Stem cell factor
improved outcome even when given late after infarct.[18] To date, in one small clinical study
of G-CSF in chronic stroke, G-CSF was tolerable but no beneficial effect was seen on outcome,
although its administration was not combined with rehabilitation therapy.[19]
In experimental stroke, pharmacological augmentation of recovery is dependent on
enriched environment and stimulation–hence the rationale for combining G-CSF and physio-
therapy.[20] We hypothesised that in chronic stroke intensive therapy can stimulate use depen-
dent plasticity, which may be augmented by G-CSF. The factorial design of this pilot
randomised controlled trial tests the feasibility of investigating this theory further.
Methods
We performed a prospective blinded-outcome, single-centre, two-by-two factorial randomised
(1:1) placebo-controlled trial of G-CSF (Filgastrim, 1x10E6 iu/kg) and/or rehabilitation therapy
in 60 adults three months to two years post stroke. Participants had to demonstrate residual
disability (modified Rankin scale, mRS>1) and no longer be receiving on-going rehabilitation.
Exclusion criteria were inability to provide informed consent; lack of residual motor deficit; sig-
nificant cognitive impairment that will impede ability to complete assessments; diagnosis likely
to interfere with outcome or rehabilitation (e.g. terminal illness); still receiving post stroke
rehabilitation; pregnancy; and other exclusions of G-CSF as listed in the British National For-
mulary. Potentially eligible patients were identified by clinical staff from Nottingham Univer-
sity Hospital stroke service, NHS Nottingham City and NHS Nottinghamshire County
community stroke teams, who sought verbal permission from the patient or representative to
be screened for eligibility for the study. Eligible patients were then approached for participation
by the research team. All participants provided written informed consent.
The study was approved by the Yorkshire and Humber Research Committee (11/YH/0138,
20/06/2011), had a Medicines and Healthcare products Regulatory Agency Clinical Trial
Authorisation (13/05/2011-11015). The study was prospectively submitted for ISRCTN regis-
tration on 28/07/2015 before the recruitment of the first participant. Following this submission,
there were no subsequent changes to the information as supplied in the study record. Study
recruitment started on 01/11/2011. Registration ISRCTN16714730 occurred on 8th December
after the NIHR confirmed the study had been adopted to NIHR portfolio. The study was per-
formed according to the Declaration of Helsinki and the International Conference on Harmo-
nisation of Good Clinical Practice.
Funding
The study was funded by National Institute Health Research, Research for Patient Benefit
(RfPB) Grant.
Randomisation
Randomisation was performed using minimisation to reduce baseline imbalances; minimisa-
tion was performed on: age; gender; time from stroke; motor function (Rivermead Motor
Assessment, RMA. In 5% of randomisations, assignment was reversed so as to reduce predict-
ability. Drug treatment allocation was concealed to all research staff and participants through-
out the study. Only the treating research therapist and participant knew the therapy group
allocation.
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Intervention
Participants received a subcutaneous injection once/day on 5 consecutive days at home of
either G-CSF or placebo (normal saline 0.9%) in identical syringes (administered by a research
nurse) and a rehabilitation intervention (of 18 home-based therapy sessions) or standard care
(no additional rehabilitation) (Fig 1). Dosing of both interventions was based on previous
research, with G-CSF after stroke,[13] and evidence that 17 hours of therapy improved out-
come after stroke.[21]
Those randomised to the rehabilitation intervention were allocated to receive 18 sessions 45
minutes long, 3 times a week, for 6 weeks. Rehabilitation was delivered by a research physio-
therapist using a patient orientated goal approach, tailored to the patient’s individual needs,
with sessions at a time of patients choosing. Where appropriate, independent exercise pro-
grammes were issued for the patient to continue rehabilitation in their own time, if they wished
to do so, as would occur in routine practice. Carers were also encouraged to be involved in
rehabilitation where appropriate. Those randomised to the standard card intervention received
no additional therapy.
Fig 1. Recruitment flow chart.
doi:10.1371/journal.pone.0161359.g001
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The primary outcomes were feasibility (proportion of participants receiving all 5 G-CSF/
placebo injections, proportion of participants receiving all therapy sessions); acceptability (pro-
portion of participants screened who are eligible for enrolment who give consent); and tolera-
bility -adverse events (headache, backache, flu like symptoms) after drug administration,
proportion of participants who decline rehabilitation therapy sessions.
Secondary outcomes included haematological measures (Day 5 CD34+ count, full blood
count, platelet count); safety; end of follow-up (Day 90) death (cause), stroke recurrence, infec-
tion and serious adverse events (SAE). Clinical exploratory efficacy measures were performed
face to face at baseline, Day 45, Day 90, Day 365 and included motor function (Rivermead
Motor Assessment, RMA)[22]; dependency (mRS) shift)[23]; disability (change in Barthel
Index, BI)[24]; quality of life (EuroQoL)[25]; Nottingham extended activities of daily living
(NEADL)[26], Mini-mental state examination (MMSE)[27], mood (Zung)[28] and care giver
burden (GHQ-28)[29]. All follow-up assessments were performed blinded to treatment alloca-
tion and laboratory results. Serious adverse events were reviewed independently, blinded to
treatment allocation and categorised using standard definitions.[30]
Statistics
As a pilot study assessing feasibility, no formal sample size calculation was performed. A sam-
ple size of 60 was deemed a priori to be adequate to test the feasibility and safety of the inter-
ventions; the sample size was not designed to test formally efficacy or interaction between the
interventions. The primary and secondary outcomes were compared between participants ran-
domised to G-CSF versus placebo (intention-to-treat) and therapy versus control. Compari-
sons between groups are by Chi-Square, t-test or ANOVA and a p value< 0.05 is considered
significant. Interaction between G-CSF and therapy is tested by ordinal logistic regression
(using mRS score at day 90 as the response variable and G-CSF, Therapy, G-CSFTherapy
[interaction term], Age, Sex, mRS and NIHSS scores at baseline and time from stroke to rando-
misation as covariates). Analyses were performed using SAS version 9.3. No corrections for
multiple statistical tests were performed.
Results
60 participants were recruited between 21st November 2011 and July 2013. The recruitment
flow chart is shown in Fig 1. Last patient visit was 21st May 2014. The baseline characteristics
were well matched across the treatment groups (Table 1), mean age 66.2 years, total anterior
circulation stroke syndrome 45%, recruited at a mean of 347 days after stroke, with residual
dependency (mean mRS 3.1).
Primary outcome: Recruitment to the trial was feasible and acceptable; with 60 participants
recruited (out of 118 screened). 32 out of 92 declined to participate. All participants received
some of their allocated treatment.
G-CSF/placebo administration
Feasibility: All patients received their randomised treatment allocation. 29 out of 30 partici-
pants received all 5 injections; 1 patient in the G-CSF group discontinued the treatment after 4
days due to an adverse event (headache).
Tolerability: More patients reported adverse events in the G-CSF group (Table D in S1 file).
Similarly, more patients in the G-CSF group (n = 9) reported serious adverse events than in the
control group (3), although this was not statistically significant (p = 0.10) (Table 2).
Functional Outcomes: There was no significant difference in dependency or disability out-
comes between the G-CSF and control treatment groups. In univariate analysis, using a t-test
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to compare the mean differences, there was significant improvement in EQ-5D QoL in the
G-CSF group (Table 3, Fig 2).
This remained significant following adjustment for Age, Sex, mRS and NIHSS scores at
baseline and time from stroke to randomisation as covariates.(p = 0.037)
Haematological outcomes: G-CSF significantly increased white cell and CD34 counts, dem-
onstrating that it was effective at mobilising haematopoietic stem cells. There were no effects
on red cell or platelet count (Table B in S1 File).
Rehabilitation/no rehabilitation
Feasibility: All patients received their randomised treatment allocation. Only 7 (23%) partici-
pants received all 18 sessions; just over half, 16 (53%), missed more than 3 sessions. On average
Table 1. Baseline characteristics by treatment groups. Data are shown as mean (standard deviation) and number (%).
Baseline Factor G-CSF G-CSF Placebo Placebo All
Rehab No rehab Rehab No rehab
N = 17 N = 13 N = 13 N = 17 N = 60
Age*, mean (SD) 66.8 (8.1) 66.8 (9.0) 64.0 (11.2) 66.9 (14.1) 66.2 (10.7)
Male*, n (%) 11 (65) 6 (46) 8 (62) 11 (65) 36 (60)
Time since stroke* (days) 347.9 (138.0) 335.1 (141.4) 348.2 (136.1) 355.0 (152.5) 347.2 (139.1)
mRS, mean (SD) 3.2 (0.95) 3.2 (0.99) 3.1 (0.95) 3.1 (0.86) 3.1 (0.91)
RMA*, mean (SD) 16.9 (11.2) 18.8 (9.3) 19.2 (9.5) 16.9 (8.2) 17.8 (9.5)
NIHSS, mean (SD) 7.2 (5.3) 6.1 (4.0) 5.6 (3.8) 6.2 (3.9) 6.3 (4.3)
TACS n (%) 8 (47) 6 (46) 5 (38) 8 (47) 27 (45)
PACS n (%) 4 (24) 4 (31) 3 (23) 3 (18) 14 (23)
LACS n (%) 4 (24) 1 (8) 4 (31) 4 (24) 13 (22)
Prior stroke, n (%) 7 (41) 3 (23) 3 (23) 2 (12) 15 (25)
History TIA, n (%) 3 (18) 2 (15) 1 (8) 4 (24) 10 (17)
Hypertension, n (%) 15 (88) 10 (77) 8 (62) 14 (82) 47 (78)
History AF, n (%) 5 (29) 3 (23) 3 (23) 6 (35) 17 (28)
History diabetes, n (%) 5 (29) 6 (46) 4 (31) 6 (35) 21 (35)
*Minimisation data; mean (standard deviation SD) mRS modiﬁed Rankin scale; RMA, Rivermead motor assessment; NIHSS National Institutes of Health
Stroke Scale; TACS total anterior circulation syndrome; PACS partial anterior circulation syndrome; LACS lacunar stroke syndrome; TIA transient ischaemic
attack, AF atrial ﬁbrillation.
doi:10.1371/journal.pone.0161359.t001
Table 2. Serious Adverse Events, by group and time to event in days; includes all SAEs up to day 90, and any fatal SAEs post day 90.
Serious Adverse Events
Time to event Group A Group B Group C Group D
GCSF and Therapy N = 17 GCSF and No therapy
N = 13
No GCSF and Therapy
N = 13
No GCSF No Therapy
N = 17
Immediate 14 days UTI Hyperglycaemia
Neutrophilia
Early 15–42 days Shingles Ischaemic stroke UTI Seizure
Cellulitis
Late 43–90 days Ischaemic stroke, Muscle Cramps, Fracture
neck femur
Seizure, Overdose Ischaemic stroke
Fatal SAEs (days after
treatment)
Fracture neck femur (244), Peripheral
vascular disease (322)
Pneumonia (306) Cardiac failure (129)
doi:10.1371/journal.pone.0161359.t002
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patients received 14 therapy sessions, (interquartile range 12 to 17). The distribution of therapy
sessions received by patients overall and by group is shown in Figs A, B and C in S2 File. The
most common reason for missing a therapy session was patient unavailability (illness: 62 ses-
sions; social/family commitments: 22 sessions; medical appointment: 8 sessions; fall: 2 ses-
sions). A number of therapy sessions (4%) were also missed due to therapist availability. There
were no significant differences in age, gender and stroke severity between those that had all
their therapy sessions versus those that did not (Table C in S1 File).
Tolerability: There were 6 patients each with serious adverse events in the rehabilitation and
control groups (Table 2). Patients in the rehabilitation group were less likely to report falls at
day 45 and day 90 than those in the no rehabilitation group (day 45: 23.3% vs. 33.3%, p = 0.57;
and day 90: 13% vs. 30%, p = 0.20) but this was not statistically significant (Table D in S1 File).
Functional Outcomes: There were no significant differences in outcomes between the ther-
apy and no therapy groups, and no consistent trends in change from baseline to day 90 and
day 365. (Table 3) Patients in the therapy group showed improvement in Rivermead Motor
Assessment at end of therapy (Day 45), but this was not statistically significant (Fig 2).
Haematological outcomes: There were no effect on haematological measures between the
therapy and no therapy groups. Platelet count was statistically different between the groups,
but this was present at baseline and not clinically significant (Table B in S1 File).
Interaction between interventions: In multivariate ordinal logistic regression, there was no
significant evidence of an interaction between the two interventions G -CSF and therapy (OR
1.20, 95% CI [0.14, 10.64], p = 0.87). The only significant predictor of outcome was baseline
function assessed as the mRS.
Data completion: Fig 1
Day 90: No participants died during the 90 day follow up period. 2 participants withdrew from
the trial before day 90–1 was in the no therapy group and expressed disappointment at not
receiving therapy. 2 participants were lost to follow-up (1 G-CSF and therapy group, 1 placebo
and therapy) by day 90.
Day 365: 3 participants died in the G-CSF group and 1 in the placebo group. (Table 2) More
participants were either lost or withdrawn at day 365 (total 5 lost, 6 withdrawn) compared to
Table 3. Treatment group comparison of the mean difference in outcome between baseline and day 90; G-CSF vs. No G-CSF and Therapy vs. No
therapy.
Outcome G-CSF No G-CSF N = 30 2p Therapy N = 30 No Therapy N = 30 2p
N = 30
Modiﬁed Rankin scale (mRS) -0.37 -0.22 0.46 -0.29 -0.31 0.90
NIHSS -0.93 -0.96 0.96 -0.88 -1 0.88
Barthel index (BI) -2.76 -3.33 0.87 -3.33 -2.76 0.87
Rivermead motor assessment (RMA) 2.03 0.81 0.23 2.37 0.59 0.072
Berg balance scale (BBS) 2.52 -0.48 0.18 2.96 -0.69 0.091
EuroQoL-5D 0.15 -0.02 0.048 0.12 0.02 0.26
EuroQoL VAS 11.12 8.48 0.66 8.1 11.48 0.57
Zung depression scale -2.39 -0.15 0.37 -2 -0.61 0.58
NE-ADL 3.48 0.22 0.39 4.3 -0.31 0.22
Mini-mental state examination (MMSE) 1.07 0.96 0.92 0.81 1.21 0.69
Carer giver burden: (GHQ-28) 0.5 10.44 0.14 3.91 5.7 0.81
National Institutes of Health Stroke Scale (NIHSS); Nottingham extended activities of daily living (NE-ADL)general health questionnaire (GHQ-28).
doi:10.1371/journal.pone.0161359.t003
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day 90 (2 withdrawn). Four of the six withdrawn participants were randomised to no
physiotherapy.
Consort checklist (S1 Checklist) and CTIMP protocol (S1 Protocol) are provided as sup-
porting information files.
Discussion
In this trial, using a factorial design, we have demonstrated that it is feasible to enrol partici-
pants with chronic stroke from the community. Recruitment was as planned and potential par-
ticipants straightforward to identify. Two thirds of potentially eligible participants chose to
participate, higher than seen in other studies.[31] This perhaps reflects both the burden of
need amongst stroke survivors and their carers, and willingness to explore the potential of
drugs to improve outcome after stroke.[32] It was feasible to deliver the drug G-CSF in the
Fig 2. Recovery outcomemeasures by treatment group (bars represent the standard error). a) Rivermead Motor Assessment (RMA) by G-CSF vs.
placebo. b) Quality of life (EQ-5D) by G-CSF vs. placebo. c) Rivermead Motor Assessment (RMA) by physiotherapy vs. control. d) Quality of life (EQ-5D) by
physiotherapy vs. control.
doi:10.1371/journal.pone.0161359.g002
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community, and G-CSF was, on the whole, well tolerated. However, not all participants rando-
mised to physiotherapy received the planned quantity of sessions. This was despite the thera-
pist being flexible regarding timing of therapy sessions. Anecdotally, participants and their
clinicians reported that they found randomisation to no additional physiotherapy less accept-
able. This is being explored in a qualitative sub-study that is being prepared for publication.
[33]
Exploratory measures of efficacy showed no differences in outcome in the G-CSF group,
although the trial was not powered to test outcome and a difference cannot be excluded.
Although there was significant improvement in quality of life this finding could be due to
chance, as we did not perform multiple statistical tests. The only other study of G-CSF in
chronic stroke included participants with very minor residual motor deficit. Although trends
to improved outcomes were demonstrated with G-CSF, methodological issues limit interpreta-
tion of this study.[19] Any potential benefit in chronic stroke would be in contrast to results in
hyperacute stroke. In the large AXIS-2 study,[34] G-CSF showed no evidence of efficacy in 328
patients with hyperacute stroke. However, AXIS-2, was testing a neuroprotective paradigm,
rather than the neuroreparative one tested here. Furthermore, recent experimental data has
shown that the dose used in AXIS-2 is likely to have lead to significant immunomodulation,
with possible modulation of T cell response and dendritic cells,[35] the safety consequences of
which are unknown in acute stroke.
This study provides more safety data on the use of G-CSF after stroke. Despite an expected
increase in reported adverse events, all but one participant tolerated a full 5 day course of
G-CSF. As seen in previous stroke studies, there were more SAEs in the G-CSF group, and
some of these (infections, vascular events) were possibly related to G-CSF treatment. This is in
keeping with data from haematology and oncology studies over many decades, where G-CSF
was well tolerated,[36] and side effects of G-CSF treatment are self-limiting and clinically
acceptable.[37]
The rehabilitation intervention was safe and there were no increase in falls or SAEs. Partici-
pants allocated to therapy did show improvement in function at day 45 (end-of-treatment)
although this was not statistically significant at end-of-follow up. However, less than a quarter
of patients received all of their allocated therapy sessions, predominantly due to patient factors
rather than therapist availability. There was no difference in therapy session delivery between
the G-CSF group and the placebo group. The feasibility of delivering such a therapy interven-
tion (3 sessions/week) so long after stroke therefore appears to be sub-optimal. This lower-
than-expected uptake of therapy sessions is in contrast to some other research studies,[38, 39]
and may relate to a number of factors including type of participants (with varying deficits) and
limited staff (with only one physiotherapist available). However another therapy intervention
delivered to chronic stroke survivors has also shown limited uptake of sessions. [40] This may
reflect clinical practice, where in reality many patients miss sessions for a variety of reasons.
Assessing fidelity of the therapy intervention also needs to capture more subjective factors
such as content of therapy, patient motivation and patient relationship with the therapist. For
instance, the number of sessions attended or length of therapy session may not be the best way
to record intensity.[31] These factors would be best explored through qualitative research,
beyond the scope of the present work.
Feedback from participants highlighted a number of issues with the trial design. In order to
allow for a control therapy group we deliberately only included patients who had already been
discharged from therapy prior to enrolment. Despite undergoing a comprehensive informed
consent process, some patients were unsurprisingly disappointed to not receive additional ther-
apy. This led to selection bias when clinicians recognised that emotional distress caused by ran-
domisation to the control (no physical therapy) group would not be well tolerated and did not
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recommend patients for participation in the trial. Hence, this design may not be appropriate
for future studies, where it may be preferable to deliver G-CSF alongside on-going rehabilita-
tion. We did not deliver a cross over design as this would have precluded long term follow-up,
which is critical when measuring recovery after stroke.
This study has a number of limitations; foremost this was a feasibility study performed in a
single centre, and experience of participants may not reflect those seen in other centres. Fur-
thermore, a heterogeneous group of participants was included, and this may limit potential to
detect efficacy. Animal data is based on models of large artery occlusion, as seen clinically in
cortical infarction–there is no experimental data in lacunar stroke or small vessel disease.[41]
However, the only clinical study of G-CSF in chronic stroke was performed in elderly patients
with white matter disease.[19] When this study was developed in conjunction with stroke sur-
vivors, they strongly argued for broad inclusion criteria, to make the study more accessible and
the results generalizable. Whilst this is important in a definitive phase 3 study, it may have
compromised the likelihood of achieving interpretable findings in this phase 2 study. Unfortu-
nately study funding did not permit multi-disciplinary rehabilitation therapy input so physio-
therapy was chosen to focus on motor recovery. We did however explore efficacy in other
domains including cognition, mood and quality of life. A number of studies have recently
shown significant differences in the outcome of patient reported quality of life,[42] as we did
here with G-CSF. This finding warrants further exploration. Finally, the timing and duration of
the therapy intervention in this population may have been too little too late. Experimental
models showing that plasticity is greatest earlier after stroke,[7] and that recovery is related to
use-dependent.[43] Therapy so late after stroke may be better aimed at preventing deteriora-
tion, rather than stimulating plasticity. Future work should focus on participants where stimu-
lating plasticity is more like, earlier after stroke.
In summary, this is the first study to assess the feasibly of testing the combination of G-CSF
and physiotherapy in chronic stroke. Whilst delivery of G-CSF in chronic stroke was feasible
and well tolerated, the acceptability of being randomised to no physiotherapy was a limiting
factor, and we failed to achieve the planned quantity of additional therapy. As such, we believe
larger factorial trials to study the combination of G-SF and physiotherapy using this design are
not supported. Future work should focus on safety and efficacy of G-CSF given earlier after
stroke onset, alongside on-going clinical rehabilitation, to stimulate use dependent plasticity.
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